Mouse/Rat S100A8/S100A9 ELISA Kit

Sample

Stool, serum, plasma, urine, tissue extract, cell culture supernatant

Species Reactivity

Mouse; Rat

Detection Method

sELISA

Intended Use

The described Enzyme-Linked-Immuno-Sorbent-Assay (ELISA) Kit is intended for the quantitative determination of S100A8/S100A9 (Calprotectin, MRP (8/14) in stool, serum, plasma, urine, tissue extract and cell culture supernatant. For research use only. Not for use in diagnostic procedures.

Contents of Kit

1. PLATE Microtiter plate, pre-coated 12 × 8 wells
2. WASHBUF Wash buffer concentrate, 10x, 2 × 100 ml
3. EXBUF Extraction buffer concentrate, 2.5×, 90 ml
4. Detection antibody concentrate,(monoclonal anti-S100A8/S100A9 antibody), lyophilised 250 μl
5. STD S100A8/S100A9 standards, lyophilised (0; 0.25; 0.98; 3.9; 15.6 ng/ml) 2 × 5 vials
6. CTRL1 Controls, lyophilised (see specification for range) 2 × 1 vial
7. CTRL2 Controls, lyophilised (see specification for range) 2 × 1 vial
8. CONJ Conjugate concentrate (anti-mouse, peroxidase labelled), 200 μl
9. SUB Substrate (tetramethylbenzidin), ready-to-use 1 × 15 ml
10. STOP Stop solution, ready-to-use 1 × 15 ml

Storage

Store all contents at 2-8°C.

Sensitivity

The Zero-standard was measured 20 times. The detection limit was set as B₀ + 3 SD and estimated to be 0.076 ng/ml.

General Description

S100A8/S100A9 (MRP (8/14) is a calcium-binding protein secreted predominantly by neutrophils and monocytes. Fecal S100A8/S100A9 is a marker for neoplasic and inflammatory gastrointestinal diseases.
It is often difficult to distinguish between irritable bowel syndrome and chronic inflammatory bowel disease. This leads in many cases to extensive and unnecessary colonoscopic examinations. The S100A8/S100A9 test allows clear differentiation between the two patient groups. Fecal S100A8/S100A9 levels correlate significantly with histological and endoscopic assessment of disease activity in Morbus Crohn's disease and ulcerative colitis as well as with the fecal excretion of indium-111-labelled neutrophilic granulocytes that has been suggested as the "gold standard" of disease activity in inflammatory bowel disease. However, measuring 111-indiumlabelled granulocytes is very costly (patient's hospitalisation, analysis and disposal of isotopic material) and is connected with radioactive exposition of the patients. For this reason, a repeated application to children and pregnant women is not recommended.
Elevated levels of S100A8/S100A9 are a much better predictor of relapse than standard inflammatory markers (CRP, ESR HB). Comparing this marker with standard fecal occult blood screening in colourectal cancer demonstrates clearly the diagnostic advantages of the fecal S100A8/S100A9 test. The parameter is of a high diagnostic value: If the S100A8/S100A9 level in stool is low, there is a high probability that an organic disease does not exist.